Web Results

Sorafenib

en.wikipedia.org/wiki/Sorafenib

Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer ...

Sorafenib: MedlinePlus Drug Information

medlineplus.gov/druginfo/meds/a607051.html

Aug 15, 2016 ... Sorafenib: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Sorafenib (Nexavar) | Cancer Research UK

www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/sorafenib

Apr 29, 2015 ... Read about the cancer treatment drug sorafenib, otherwise known as Nexavar, including what it is, how it works and possible side effects.

FDA Approval for Sorafenib Tosylate - National Cancer Institute

www.cancer.gov/about-cancer/treatment/drugs/fda-sorafenib-tosylate

Nov 26, 2013 ... On November 22, 2013, the Food and Drug Administration (FDA) approved sorafenib tosylate (Nexavar<sup>®</sup> tablets, made by Bayer Healthcare ...

DrugBank: Sorafenib

www.drugbank.ca/drugs/DB00398

Jun 13, 2005 ... Absorption, The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma ...

sorafenib oral : Uses, Side Effects, Interactions, Pictures, Warnings ...

www.webmd.com/drugs/2/drug-94784/sorafenib-oral/details

Find patient medical information for sorafenib oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Sorafenib: Indications, Side Effects, Warnings - Drugs.com

www.drugs.com/cdi/sorafenib.html

Easy to read patient leaflet for sorafenib. Includes indications, proper use, special instructions, precautions, and possible side effects.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

www.ncbi.nlm.nih.gov/pubmed/19228077

Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib  ...

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that ...

www.ncbi.nlm.nih.gov/pubmed/16757355

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor ...

Sorafenib | C21H16ClF3N4O3 - PubChem

pubchem.ncbi.nlm.nih.gov/compound/Sorafenib

Sorafenib is a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the ...

More Info

Sorafenib (Nexavar) Chemotherapy Drug Information - Chemocare

chemocare.com

Sorafenib (Nexavar) side effects, what it's used for, how it's given, how it works, drug type, precautions and self care tips.

Sorafenib Tosylate - National Cancer Institute

www.cancer.gov

Oct 5, 2006 ... This page contains brief information about sorafenib tosylate and a collection of links to more information about the use of this drug, research ...

Sorafenib in Advanced Hepatocellular Carcinoma — NEJM

www.nejm.org

Original Article from The New England Journal of Medicine — Sorafenib in Advanced Hepatocellular Carcinoma.